del-brax - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Brookfield completes $3bn Oaktree buyout as credit platform reaches $365 bn

Williams to buy Momentum Midstream for $5.5bn as Haynesville LNG strategy accelerates

Snap revenue jumps 19% as AI advertising tools revive $SNAP investor confidence

Control Bionics (ASX: CBL) registers NeuroStrip with US FDA as commercial execution becomes the next test

Representative image of rare muscle disease research as Novartis AG’s del-brax data strengthens its Avidity Biosciences acquisition story, RNA therapy strategy, and facioscapulohumeral muscular dystrophy pipeline.

Read More

Pharma Industry News

Why Novartis’ $12bn Avidity bet suddenly looks more interesting after new del-brax data

Find out how Novartis AG’s del-brax data could strengthen its $12bn Avidity Biosciences bet and rare muscle disease strategy.

byPallavi Madhiraju

June 12, 2026

web analytics